Why do people develop antibodies to food? While clinicians have long observed that healthy humans develop a particular type ...

Otsuka's investigational antibody sibeprenlimab approximately halved levels of this key biomarker in patients with ...

Pfizer's CEO discussed the extensive due diligence the company has conducted on the 3SBio PD-1xVEGF deal. | Pfizer's CEO ...

Calliditas Therapeutics (Calliditas), an Asahi Kasei company, announced today that new data was presented at the 62nd European Renal Association Congress (ERA Congress), which took place in Vienna, ...

Biotechnology company GlycoEra has closed an oversubscribed Series B financing round, raising $130m, to support the progression of its lead immunoglobulin G4 (IgG4)-targeted protein degrader through ...

In the Phase III VISIONARY study, sibeprenlimab, an investigational monoclonal antibody, showed a 51.2% reduction in ...

The novel selective antibody sibeprenlimab reduced proteinuria more than any prior drug for IgA nephropathy, with excellent ...

Bound IgG were detected by a further 1-hour incubation ... The assay was then continued as a direct binding assay. HCMV UL94 protein production. The UL94 coding region was cloned in the expression ...

Otsuka's experimental therapy for a potentially life-threatening kidney disease more than halved severe levels of protein in the urine of patients, intensifying the battle for an effective new ...

The FDA has accepted for Priority Review the BLA for sibeprenlimab for the treatment of immunoglobulin A nephropathy in adults.

Sibeprenlimab clinically reduces proteinuria in adults with immunoglobulin A nephropathy (IgAN), according to data from a prespecified analysis of the phase 3 VISIONARY trial. The findings were ...